Clinical Trials Browser

Pathologic Complete Response, Rectal Neoplasms

Colorectal Neoplasms

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms, Neoplasm, Residual

Colorectal Neoplasms

Carcinoma, Hepatocellular

Biliary Tract Neoplasms

Locally Advanced Rectal Carcinoma

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular, Liver Neoplasms

Gastric Cancer Peritoneal Metastases

Colorectal Neoplasms

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Colorectal Neoplasms

Esophageal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Colorectal Neoplasms

Digestive System Neoplasms

Colonic Neoplasms

Biliary Tract Neoplasms

Rectal Neoplasms

Esophageal Squamous Cell Carcinoma

Colonic Neoplasms

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms

Stomach Neoplasms

Adenocarcinoma, Pancreatic Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Gastric Cancer Stage

Carcinoma, Hepatocellular

Stomach Neoplasms

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Esophageal Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Colonic Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Sarcoma

Colorectal Neoplasms

Esophageal Neoplasms

Carcinoma, Hepatocellular, Recurrence

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Esophageal Neoplasms, Stomach Neoplasms

Locally Advanced Rectal Cancer

Locally Recurrent Colorectal Cancer

Stomach Neoplasms

Cholangiocarcinoma

Pancreatic Ductal Adenocarcinoma

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

Clinical Trials

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

TRIUNITE06

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

Endosurgery-02

FRONT-1

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

FUTURE

NeoTISLEGA

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

MRD2START

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

HESTIA

Tislelizumab in People With Colorectal Cancer

IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

GENTIS

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

PPIO-004-EC001

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

A Benefit Population Atlas of nICT Versus nCT for LAGC

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

LEAF-01

TALENT

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

UMBRELLA

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer